Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast cancer receiving moderately or highly emetogenic chemotherapy
Crossref DOI link: https://doi.org/10.1186/s12885-016-2186-4
Published Online: 2016-02-26
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Boccia, Ralph
O’Boyle, Erin
Cooper, William
License valid from 2016-02-26